AI
Thursday, May 24, 2012 9:03:11 PM
FROI Fero Industries, Inc. DD Collection;
Contact Info:
254-16 Midlake Boulevard SE
Calgary, ALB T2X 2X7
Canada
Phone: 403-383-7663
http://www.feroindustries.com/
CUSIP: 31527F204
ISIN Code: US31527F2048
CIK: 0001409475
Authorized: 500 mil
Outstanding:151 mil
Approx Float: 98mil
Transfer Agent:
Holladay Stock Transfer
2939 N. 67th Place
Scottsdale, AZ, 85251
480-481-3940
MANAGEMENT TEAM:
http://www.feroindustries.com/mgmt-new.asp
Corporate profile of Fero Industries: (a must read!)
http://www.feroindustries.com/pdf/Fero%20Industries%20FROI%20Corporate%20Profile%20July%202011.pdf
Company Profile:
http://www.reuters.com/finance/stocks/FROI.PK/key-developments
FROI on OTC:
http://www.otcmarkets.com/stock/FROI/financials
FROI Ihub board:
http://investorshub.advfn.com/Fero-Industries-Inc-FROI-16240/
Ihub search for FROI:
http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=froi
*The Company is continuing the process to become a Certified Supplier to other federal and local government institutions, including the Instituto Nacional de Nutrición, the Instituto Nacional de Cancerología (INCAN), Secretaría de Salud del Distrito Federal, to reach over 2,500,000 potential new customers that receive their primary healthcare through these low-cost public government healthcare offices.
*FROI expected both revenues and margins to grow dramatically as new patients adopt Sucanon® into their daily type-2 diabetes management routine, and Sucanon distribution expands beyond Mexico to include countries in South America, Asia, and the Middle East."
"Fero Industries, Inc. Achieves First Certified Supplier Status to Distribute Sucanon® in Mexico":
http://www.prnewswire.com/news-releases/fero-industries-inc-achieves-first-certified-supplier-status-to-distribute-sucanon-in-mexico-135652568.html
"Sucanon Completes Clinical Trials With Outstanding Results and No Side Effects"
http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2012/01/20/prweb9125017.DTL
About Sucanon:
Sucanon® is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies show that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® has been approved for prescription sale in China and Peru. Sucanon® is also approved as an OTC treatment for type-2 diabetes by regulatory authorities in Mexico, and is distributed there under an exclusive agreement with Merck S.A. de C.V.
* FROI expanded Sucanon® retail distribution throughout Mexico from 900 points-of-sale to over 2,500 outlets and pharmacy chains. Sucanon® is available over-the-counter in Mexico from many well-known retailers including WalMart Supercenters, Superama, Farmacias del Ahorro, Comercial Mexicana, Farmacias Guadalajara, Soriana, Farmacias San Pablo, and Gusher Farmacias.
"Due to the excellent performance of Merck S.A. de C.V. as our business partners, Sucanon® is well positioned on the most important retail shelves throughout Mexico," said Mr. Luis M. Lopez, Chief Operating Officer of Fero Industries Inc. and President of Pharmaroth S.A., the Company's Mexican subsidiary. "This rapid expansion of distribution has placed Sucanon® and Sucanon® related marketing material in almost three times as many retail stores and should continue to boost market awareness and acceptance of Sucanon® as an over-the-counter treatment for type-2 diabetes across Mexico."
What is Diabetes?
Diabetes is a condition in which a person has a high blood sugar (glucose) level, either because the body do not produce enough insulin, or because body cells do not properly respond to the insulin that is produced. Insulin is a hormone produced in the pancreas which regulates glucose. Insulin enables body cells to absorb glucose and to convert it into turn into energy. If the body cells do not absorb the glucose, the glucose accumulates in the blood (hyperglycemia), leading to vascular, nerve, and other complications.
There are many types of diabetes the most common of which are:
Type I Diabetes; (previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes): results from the body's failure to produce insulin, and presently requires the person to inject insulin.
Type II Diabetes; (previously called non-insulin-dependent diabetes mellitus (NIDDM) or maturity-onset diabetes): results from insulin resistance, a condition in which cells fail to use insulin properly, sometimes combined with an absolute insulin deficiency.
The increase in the total population of diabetics, may raise total U.S. sales of insulin and oral type 2 diabetes therapies to $24.4 billion, from $10.3 billion in 2008.
What is Sucanon® ?
Sucanon® is one of only several drugs approved in the world, belonging to a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.
1. Insulin binding to receptors and entering the cell, (which is impeded in NIDDM patients), is essential for the uptake of glucose 2. Sucanon® increases the binding of insulin to its receptors 3. Sucanon® increases the internalization of insulin 4. As a result, Sucanon® increases the intracellular level of insulin, which then increases the uptake of glucose.
Clinical Trial Summary:
Clinical trials on Sucanon® were performed in China. After submission of a New Drug Application ("NDA") Sucanon® was approved by the Chinese Food and Drug Administration ("FDA"). Subsequent clinical trials were also performed on Sucanon® in Brazil. The Brazilian study showed that equivalent clinical activity occurs in a non-Asian population.
Sucanon® Regulatory Approvals:
Sucanon® has been approved for prescription sale in Peru and has been approved as an over-the-counter (non-prescription) product in Mexico. Application for United States FDA regulatory approval has not yet been made. Thus, doctors cannot prescribe nor purchase Sucanon® in the United States. However, Type II diabetics can buy Sucanon® for their own use and have it delivered to them from Mexico under the U.S. FDA's "personal importation" guidelines. A similar program exists for Type II diabetics in Canada who wish to buy Sucanon® for their own use.
Type 2 Diabetes in the News:
http://www.feroindustries.com/resources.asp
Daily chart:
http://stockcharts.com/h-sc/ui?s=FROI&p=D&b=5&g=0&id=p80585982449&listNum=1&a=267019675
Weekly chart:
http://stockcharts.com/h-sc/ui?s=FROI&p=W&b=5&g=0&id=p37313936982&listNum=1&a=267019682
http://stockcharts.com/c-sc/sc?s=FROI&p=W&b=5&g=0&i=p37313936982&a=267019682&r=1337906423906
Contact Info:
254-16 Midlake Boulevard SE
Calgary, ALB T2X 2X7
Canada
Phone: 403-383-7663
http://www.feroindustries.com/
CUSIP: 31527F204
ISIN Code: US31527F2048
CIK: 0001409475
Authorized: 500 mil
Outstanding:151 mil
Approx Float: 98mil
Transfer Agent:
Holladay Stock Transfer
2939 N. 67th Place
Scottsdale, AZ, 85251
480-481-3940
MANAGEMENT TEAM:
http://www.feroindustries.com/mgmt-new.asp
Corporate profile of Fero Industries: (a must read!)
http://www.feroindustries.com/pdf/Fero%20Industries%20FROI%20Corporate%20Profile%20July%202011.pdf
Company Profile:
http://www.reuters.com/finance/stocks/FROI.PK/key-developments
FROI on OTC:
http://www.otcmarkets.com/stock/FROI/financials
FROI Ihub board:
http://investorshub.advfn.com/Fero-Industries-Inc-FROI-16240/
Ihub search for FROI:
http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=froi
*The Company is continuing the process to become a Certified Supplier to other federal and local government institutions, including the Instituto Nacional de Nutrición, the Instituto Nacional de Cancerología (INCAN), Secretaría de Salud del Distrito Federal, to reach over 2,500,000 potential new customers that receive their primary healthcare through these low-cost public government healthcare offices.
*FROI expected both revenues and margins to grow dramatically as new patients adopt Sucanon® into their daily type-2 diabetes management routine, and Sucanon distribution expands beyond Mexico to include countries in South America, Asia, and the Middle East."
"Fero Industries, Inc. Achieves First Certified Supplier Status to Distribute Sucanon® in Mexico":
http://www.prnewswire.com/news-releases/fero-industries-inc-achieves-first-certified-supplier-status-to-distribute-sucanon-in-mexico-135652568.html
"Sucanon Completes Clinical Trials With Outstanding Results and No Side Effects"
http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2012/01/20/prweb9125017.DTL
About Sucanon:
Sucanon® is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies show that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® has been approved for prescription sale in China and Peru. Sucanon® is also approved as an OTC treatment for type-2 diabetes by regulatory authorities in Mexico, and is distributed there under an exclusive agreement with Merck S.A. de C.V.
* FROI expanded Sucanon® retail distribution throughout Mexico from 900 points-of-sale to over 2,500 outlets and pharmacy chains. Sucanon® is available over-the-counter in Mexico from many well-known retailers including WalMart Supercenters, Superama, Farmacias del Ahorro, Comercial Mexicana, Farmacias Guadalajara, Soriana, Farmacias San Pablo, and Gusher Farmacias.
"Due to the excellent performance of Merck S.A. de C.V. as our business partners, Sucanon® is well positioned on the most important retail shelves throughout Mexico," said Mr. Luis M. Lopez, Chief Operating Officer of Fero Industries Inc. and President of Pharmaroth S.A., the Company's Mexican subsidiary. "This rapid expansion of distribution has placed Sucanon® and Sucanon® related marketing material in almost three times as many retail stores and should continue to boost market awareness and acceptance of Sucanon® as an over-the-counter treatment for type-2 diabetes across Mexico."
What is Diabetes?
Diabetes is a condition in which a person has a high blood sugar (glucose) level, either because the body do not produce enough insulin, or because body cells do not properly respond to the insulin that is produced. Insulin is a hormone produced in the pancreas which regulates glucose. Insulin enables body cells to absorb glucose and to convert it into turn into energy. If the body cells do not absorb the glucose, the glucose accumulates in the blood (hyperglycemia), leading to vascular, nerve, and other complications.
There are many types of diabetes the most common of which are:
Type I Diabetes; (previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes): results from the body's failure to produce insulin, and presently requires the person to inject insulin.
Type II Diabetes; (previously called non-insulin-dependent diabetes mellitus (NIDDM) or maturity-onset diabetes): results from insulin resistance, a condition in which cells fail to use insulin properly, sometimes combined with an absolute insulin deficiency.
The increase in the total population of diabetics, may raise total U.S. sales of insulin and oral type 2 diabetes therapies to $24.4 billion, from $10.3 billion in 2008.
What is Sucanon® ?
Sucanon® is one of only several drugs approved in the world, belonging to a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.
1. Insulin binding to receptors and entering the cell, (which is impeded in NIDDM patients), is essential for the uptake of glucose 2. Sucanon® increases the binding of insulin to its receptors 3. Sucanon® increases the internalization of insulin 4. As a result, Sucanon® increases the intracellular level of insulin, which then increases the uptake of glucose.
Clinical Trial Summary:
Clinical trials on Sucanon® were performed in China. After submission of a New Drug Application ("NDA") Sucanon® was approved by the Chinese Food and Drug Administration ("FDA"). Subsequent clinical trials were also performed on Sucanon® in Brazil. The Brazilian study showed that equivalent clinical activity occurs in a non-Asian population.
Sucanon® Regulatory Approvals:
Sucanon® has been approved for prescription sale in Peru and has been approved as an over-the-counter (non-prescription) product in Mexico. Application for United States FDA regulatory approval has not yet been made. Thus, doctors cannot prescribe nor purchase Sucanon® in the United States. However, Type II diabetics can buy Sucanon® for their own use and have it delivered to them from Mexico under the U.S. FDA's "personal importation" guidelines. A similar program exists for Type II diabetics in Canada who wish to buy Sucanon® for their own use.
Type 2 Diabetes in the News:
http://www.feroindustries.com/resources.asp
Daily chart:
http://stockcharts.com/h-sc/ui?s=FROI&p=D&b=5&g=0&id=p80585982449&listNum=1&a=267019675
Weekly chart:
http://stockcharts.com/h-sc/ui?s=FROI&p=W&b=5&g=0&id=p37313936982&listNum=1&a=267019682
http://stockcharts.com/c-sc/sc?s=FROI&p=W&b=5&g=0&i=p37313936982&a=267019682&r=1337906423906
